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The mechanisms by which SGLT-2 inhibitors lower albuminuria are incompletely understood.
We assessed in a post-hoc analysis of a cross-over trial the effects of the SGLT2 inhibitor dapagliflozin on glomerular markers (IgG to IgG4 and IgG to albumin), tubular markers (urinary KIM-1, NGAL and LFABP) and inflammatory markers (urinary MCP-1 and IL-6) to provide more insight into kidney protective effects. Dapagliflozin decreased albuminuria by 43.9% (95% CI, 30.3%-54.8%) and eGFR by 5.1 (2.0-8.1) mL/min/1.73m 2 compared to placebo. Dapagliflozin did not change glomerular charge or size selectivity index compared to placebo. Dapagliflozin decreased urinary KIM-1 excretion by 22.6% (0.3%-39.8%; P = .05) and IL-6 excretion by 23.5% 
| INTRODUCTION
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors lower glycated haemoglobin (HbA1c), decrease blood pressure, body weight and albuminuria, and, in the long-term, SGLT-2 inhibitors appear to slow progression of kidney function decline. [1] [2] [3] The mechanisms responsible for the albuminurialowering effect are not yet completely understood. A reduction in glomerular hyperfiltration as a result of restoration of tubuloglomerular feedback may be 1 of the potential mechanisms. 4,5 SGLT-2 inhibitors could also hypothetically lower albuminuria by restoring the charge and/or size selectivity of the glomerular basement membrane. Alternatively, improvement in tubular reabsorption of filtered albumin can potentially decrease albuminuria. 6 SGLT-2 inhibition reduces the reabsorption of filtered sodium and glucose in the proximal tubule, and thereby reduces the oxygen-consuming transport workload. Less oxygen stress may help to improve tubular cell integrity and, potentially, tubular albumin reabsorption. 7, 8 As hyperglycaemia and albuminuria have proinflammatory influences on renal tubules, reductions in these parameters could, hypothetically, reduce the generation of proinflammatory cytokines. 9 Various biomarkers that are associated with glomerular and tubular structure and function are presently available. The aim of the current study was to characterize the effect of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury and inflammatory markers. Secondly, we assessed whether changes in albuminuria or eGFR during dapagliflozin therapy correlated with kidney injury markers to provide insight into the mechanisms responsible for the lowering of albuminuria with dapagliflozin.
| MATERIALS AND METHODS

| Study design and patients
This was a post-hoc analysis of a prospective, randomized, doubleblind, placebo-controlled cross-over clinical trial. The study design, patient population and primary results have been described previously. 10 In short, 33 patients with type 2 diabetes, aged between 18 and 75 years, with a first morning void albumin:creatinine ratio (U ACR ) ≥ 100 mg/g and < 3500 mg/g (11.3-395.5 mg/mmol) and an eGFR ≥45 mL/min/1.73m 2 were enrolled. Participants were required to have been using a maximum tolerated stable dose of an angiotensin converting enzyme inhibitor or angiotensin receptor blocker for more than 4 weeks. Patients were randomly assigned to 2 consecutive treatment periods of 6 weeks, during which they received dapagliflozin 10 mg per day or placebo, with wash-out periods of 6 weeks in between. The primary outcome was change in 24-hour urinary albumin excretion rate (24 hour UAE). The study was registered with the Netherlands Trial Register (NTR 4439) and complied with the Declaration of Helsinki and Good Clinical Practice Guidelines.
| Measurements
Blood and urine samples were obtained at baseline, in the beginning and at the end of the 2 treatment periods, as well as at the end of the wash-out period. These urine and plasma samples were stored at −80 C for no more than 24 months (range, 6-24 months). Blood and urine samples from 31 patients were available for this study.
Urinary IgG and IgG4 were measured as markers of glomerular damage. Urinary kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL) and liver-type fatty acidbinding protein (LFABP) were measured as markers of tubular damage.
Urinary monocyte chemoattractant protein-1 (MCP-1) and urinary interleukin-6 (IL-6) were measured as markers of inflammation. 11 To assess the effect of dapagliflozin on size-selectivity and chargeselectivity of the glomerular basement membrane, plasma IgG and IgG4 were also determined. The ratio of IgG to albumin clearance was calculated as an index of glomerular size selectivity. 12 Glomerular charge selectivity was calculated by the ratio of the clearance of the neutrally charged IgG to the clearance of the negatively charged IgG4. 12 For quantification of IgG4, KIM-1, NGAL, LFABP, MCP-1 and IL-6, direct sandwich-ELISAs were used according to the manufacturer's specifications (R&D systems, Minneapolis, Minnesota). IgG was quantified with nephelometry.
| Statistical analysis
The effect of dapagliflozin compared to placebo on the kidney injury 
| RESULTS
Baseline characteristics of the 31 patients with available urine and plasma samples are reported online in Table S1 . Dapagliflozin decreased 24 hour UAE by 42.5% (95% CI, 29.9%-52.9%; P < .01) and eGFR by 5.2 mL/min/1.73m 2 (2.5-7.8 mL/min/1.73m 2 ; P < .01) ( Figure 1A,B ). The decrease in eGFR occurred within the first weeks of dapagliflozin therapy. Six weeks after dapagliflozin discontinuation the mean eGFR was 71 (SD, 19) ml/min/1.73m 2 , indicating that the decline in eGFR was reversible after treatment discontinuation. (Table S2) . suggesting that SGLT-2 inhibitors induce structural improvements in the kidney over time. 13 Dapagliflozin appeared to decrease urinary KIM-1 excretion, but there was no effect on urinary NGAL and LFAPB excretion, compared to placebo. KIM-1 is a specific marker for hypoxic injury to proximal tubular cells, which would suggest that dapagliflozin reduces proximal tubular cell injury. 14 The reabsorption of electrolyte and organic solutes in the proximal tubule requires much energy. 7 The proximal tubule therefore accounts for the largest amount of oxygen consumption in the kidney. SGLT-2 expression is increased in patients with diabetes. 5 As a result, more glucose and sodium are reabsorbed, which increases the oxygen demand of tubular cells. This, in turn, renders the proximal tubule particularly susceptible to hypoxia in the setting of type 2 diabetes. 7, 8 Hypoxia appears to be one of the major drivers of kidney disease progression, especially in the diabetic kidney. 8, 15 SGLT-2 inhibition reduces sodium and glucose reabsorption in the proximal tubule, thereby reducing the workload for proximal tubular cells. Reduced workload may mitigate hypoxia-induced proximal tubular damage, which could lead to improved tubular cell structural integrity and, possibly, function. 7, 8 This notion is supported by a previous animal study showing that SGLT inhibition with phlorizin in diabetic rats improved renal cortical oxygen tension. 16 We also observed a reduction in the inflammatory marker IL-6 during dapagliflozin treatment. IL-6 is an inflammatory cytokine and has been implicated in the progression of diabetic kidney disease. 17 The presence of cytokines in the urine is thought to reflect local renal production of these cytokines. 18, 19 The decrease of IL-6 excretion observed in our study is in line with previous animal and in vitro studies. 20, 21 Previous studies showed that increased albumin leakage into the tubular compartment triggers an inflammatory response leading to MCP-1 and IL-6 release. 22 The reduction in albumin leakage or tubular reabsorption may alleviate intra-renal inflammation and release of IL-6 and MCP-1. It is also possible that increasing urinary glucose excretion reduces intra-renal glucotoxicity and inflammation. 9 Unfortunately, urinary glucose excretion was not measured in our study.
| Effect of dapagliflozin on glomerular, tubular and inflammatory markers
| Correlations between 24 hour UAE, eGFR and kidney injury markers
| DISCUSSION
To the best of our knowledge, our study is the first to investigate the effect of SGLT-2 inhibition on tubular injury markers. Our data demonstrate that dapagliflozin does not increase tubular injury markers. In addition, the absence of correlation between changes in eGFR and changes in kidney injury markers indicates that 6-weeks This study has limitations. It was performed as a post-hoc analysis of a short-term study. As such, we were unable to investigate the long-term effects of SGLT-2 inhibition on glomerular, tubular and inflammatory biomarkers. It is not clear whether the results would apply to the sustained effects of dapagliflozin. In addition, because of the relatively small sample size, the power may have been too low to detect significant changes in, for example, the proxies for glomerular charge and size selectivity. These results should, thus, be regarded as hypothesis generating rather than hypothesis testing.
In conclusion, dapagliflozin therapy for 6 weeks decreases urinary excretion of proximal tubular marker KIM-1 and inflammatory marker IL-6. The observed reduction in albuminuria correlated positively with the decrease in eGFR, and also with the reduction in KIM-1 excretion.
These findings support the hypothesis that the albuminuria-lowering effect of dapagliflozin could be the result of a reduction in glomerular pressure and improved proximal tubular cell integrity.
